Aclaris buys Confluence Life Sciences for $20mm plus $80mm in earn-outs
Aclaris Therapeutics Inc. acquired private kinase inhibitor firm Confluence Life Sciences Inc. for $20mm up front ($10mm in cash and $10mm in Aclaris common shares). Confluence shareholders could also get up to $80mm in earn-outs for development, regulatory, and sales achievements, plus low-single-digit royalties.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.